Compounds > procaine
Page last updated: 2024-11-03

procaine and Heart Defects, Congenital

procaine has been researched along with Heart Defects, Congenital in 17 studies

Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research Excerpts

ExcerptRelevanceReference
"33."2.87Role of terminal warm blood cardioplegia in complex congenital heart surgery. ( Boom, CE; Busro, PW; Jusuf, AA; Rachmat, J; Romolo, H; Sadikin, M; Santoso, A; Sastroasmoro, S; Suwarto, S, 2018)
"From June 1995 to July 1997, we treated 32 congenital heart disease patients using Bretschneider cardioplegic solution and 20 patients using blood cardioplegia."1.30[Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery]. ( Asano, H; Kobayashi, J; Kobayashi, T; Koike, K; Kyo, S; Ogiwara, M; Omoto, R; Taketazu, M; Tsunemoto, M; Yokote, Y, 1999)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-199010 (58.82)18.7374
1990's1 (5.88)18.2507
2000's0 (0.00)29.6817
2010's6 (35.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, J1
Wu, Y1
Tian, X1
Wang, J1
Dong, M1
Wang, A1
Ma, S1
Busro, PW1
Romolo, H1
Sastroasmoro, S1
Rachmat, J1
Sadikin, M1
Santoso, A1
Boom, CE1
Suwarto, S1
Jusuf, AA1
Valente, AS1
Lustosa, GP1
Mota, LAM1
Lima, A1
Mesquita, FA1
Gondim, A1
Rodrigues, FA1
Pompeu, RG1
Branco, KC1
Bojan, M1
Peperstraete, H1
Lilot, M1
Tourneur, L1
Vouhé, P1
Pouard, P1
Ma, C1
Shen, DR1
Zhang, Q1
Meng, XC1
Wang, YX1
Peng, L1
Meng, BY1
Li, XW1
Lin, YZ1
Lin, H1
Huang, JB1
Tang, XM1
Long, XM1
Lu, WJ1
Wen, ZK1
Liang, J1
Li, DY1
Zhao, XF1
ACTIS DATO, A1
GENTILLI, R1
Steinfeld, L1
Rappaport, HR1
Dragoĭchev, Ch1
Daskalov, E1
Konstantinov, P1
Madzharov, D1
Asano, H1
Kyo, S1
Ogiwara, M1
Tsunemoto, M1
Yokote, Y1
Omoto, R1
Koike, K1
Kobayashi, T1
Kobayashi, J1
Taketazu, M1
Di Summa, M1
Carletta, C1
Morea, M1
Hoffmeister, HE1
Seboldt, H1
Seybold-Epting, W1
Stunkat, R1
Regensburger, D1
Hellberg, K1
Knoll, D1
Ruschewski, W1
Schenk, HD1
Sonntag, H1
de Vivie, R1
Wolfram-Donath, U1
Stefaniak, B1
Zasłonka, J1
Jaszewski, R1
Zwoliński, M1
Iwaszkiewicz, A1
Kesiak, J1
Rychter, J1
Lewandowski, R1
Mussur, M1
Nasseri, M1
Bücherl, ES1
Herbst, R1
Lorkiewicz, Z1
Borzycka, B1
Ponizyński, A1
Blotna-Filipiak, M1
Kirsch, U1
Rodewald, G1
Kalmár, P1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Custodiol Versus Blood Cardioplegaia in Paediatric Cardiac Surgery[NCT03082716]Phase 249 participants (Actual)Interventional2016-03-16Completed
Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095]Phase 2110 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All Cause Mortality

Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution20
Cold Blood Cardioplegia24

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution6.0
Cold Blood Cardioplegia7.8

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution1.9
Cold Blood Cardioplegia2.6

Cardiac Dysrhythmias

Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution24
Cold Blood Cardioplegia30

Cardiac Marker - Troponin-I

Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution5.7
Cold Blood Cardioplegia7.8

Cardiac Marker - Troponin-I

Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution3.0
Cold Blood Cardioplegia4.8

Cardiac Marker - Troponin-I

Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution.03
Cold Blood Cardioplegia.03

Cardiovascular Mortality

Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB)

Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution18.8
Cold Blood Cardioplegia22.2

Change in Troponin I

Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution9.65
Cold Blood Cardioplegia10.15

Changes in Left Ventricular (LV) Ejection Fraction (EF) by Transthoracic Echocardiogram (TTE)

LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery

Intervention% LV volume (Mean)
Cardioplegia: Custodiol HTK Solution-0.06
Cold Blood Cardioplegia1.9

Duration of Vasopressor / Inotropic Agent

Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionminutes (Median)
Cardioplegia: Custodiol HTK Solution340
Cold Blood Cardioplegia582

Intensive Care Unit (ICU) Length of Stay

Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission

Interventiondays (Median)
Cardioplegia: Custodiol HTK Solution3
Cold Blood Cardioplegia3

Myocardial Infarction

Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Postoperative Inotropic Infusion >20 Minutes

Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution47
Cold Blood Cardioplegia43

Time on Mechanically Assisted Ventilation

time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionhours (Median)
Cardioplegia: Custodiol HTK Solution10.5
Cold Blood Cardioplegia11.4

Reviews

1 review available for procaine and Heart Defects, Congenital

ArticleYear
[Hypothermia and cardioplegia in extracorporeal circulation: personal experience].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1985, Jul-15, Volume: 40, Issue:28

    Topics: Adult; Aspartic Acid; Child; Coronary Artery Bypass; Extracorporeal Circulation; Heart Arrest, Induc

1985

Trials

3 trials available for procaine and Heart Defects, Congenital

ArticleYear
Role of terminal warm blood cardioplegia in complex congenital heart surgery.
    Asian cardiovascular & thoracic annals, 2018, Volume: 26, Issue:3

    Topics: Apoptosis; Arrhythmias, Cardiac; Biomarkers; Cardiac Output, Low; Cardioplegic Solutions; Caspase 3;

2018
Comparative Analysis of Myocardial Protection with HTK Solution and Hypothermic Hyperkalemic Blood Solution in the Correction of Acyanogenic Congenital Cardiopathies - A Randomized Study.
    Brazilian journal of cardiovascular surgery, 2019, 06-01, Volume: 34, Issue:3

    Topics: Analysis of Variance; Cardioplegic Solutions; Creatine Kinase, MB Form; Double-Blind Method; Echocar

2019
[Protective effect of cold autologous blood cardioplegic solution on the heart of infants with cyanotic congenital heart disease].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2013, Volume: 15, Issue:6

    Topics: Cardioplegic Solutions; Cardiopulmonary Bypass; Energy Metabolism; Female; Glucose; Heart Defects, C

2013

Other Studies

13 other studies available for procaine and Heart Defects, Congenital

ArticleYear
Protective effect of HTK solution on postoperative pulmonary function in infants with CHD and PAH.
    Bioscience reports, 2017, Dec-22, Volume: 37, Issue:6

    Topics: Cardiopulmonary Bypass; Child, Preschool; Female; Glucose; Heart Defects, Congenital; Humans; Hypert

2017
Cold histidine-tryptophan-ketoglutarate solution and repeated oxygenated warm blood cardioplegia in neonates with arterial switch operation.
    The Annals of thoracic surgery, 2013, Volume: 95, Issue:4

    Topics: Blood Transfusion; Cardiac Surgical Procedures; Cardioplegic Solutions; Coronary Vessels; Female; Fo

2013
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Volume: 49, Issue:6

    Topics: Analysis of Variance; Cardioplegic Solutions; Cardiopulmonary Bypass; Child, Preschool; Female; Gluc

2016
[Changes in the ECG pattern caused by peroperative injection of novocain into the sino-atrial node in man].
    Minerva cardioangiologica, 1958, Volume: 6, Issue:9

    Topics: Congenital Abnormalities; Electrocardiography; Heart Defects, Congenital; Heart Septal Defects; Hear

1958
Cardiac catheterization in the diagnosis of congenital heart disease in infants.
    Advances in cardiopulmonary diseases, 1966, Volume: 3

    Topics: Anesthetics, Local; Angiocardiography; Cardiac Catheterization; Heart Defects, Congenital; Humans; I

1966
[Initial results of using Cardioplegin in heart operations].
    Khirurgiia, 1981, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Aspartic Acid; Child; Child, Preschool; Drug Combinations

1981
[Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery].
    Kyobu geka. The Japanese journal of thoracic surgery, 1999, Volume: 52, Issue:1

    Topics: Cardiac Surgical Procedures; Cardioplegic Solutions; Child, Preschool; Glucose; Heart Arrest, Induce

1999
[Myocardial protection from cardioplegic and hypothermia during aortic cross-clamping (author's ttrans)].
    Giornale italiano di cardiologia, 1979, Volume: 9, Issue:3

    Topics: Adenosine Triphosphate; Aorta; Calcium Chloride; Cardiac Surgical Procedures; Constriction; Coronary

1979
[Myocardial protection utilizing hypothermia and cardioplegin during surgical correction of congenital heart disease (author's transl)].
    Thoraxchirurgie, vaskulare Chirurgie, 1978, Volume: 26, Issue:2

    Topics: Aspartic Acid; Heart Arrest, Induced; Heart Defects, Congenital; Humans; Hypothermia, Induced; Magne

1978
[Coronary circulation and myocardial oxygen cosumption after cardioplegic arrest (author's transl)].
    Thoraxchirurgie, vaskulare Chirurgie, 1975, Volume: 23, Issue:3

    Topics: Acid-Base Equilibrium; Aspartic Acid; Cardiac Output; Cardiopulmonary Bypass; Coronary Circulation;

1975
[Practical experiences using procaine magnesium aspartate in open heart surgery].
    Thoraxchirurgie, vaskulare Chirurgie, 1973, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aspartic Acid; Biopsy; Child; Coronary Disease; Electrocardiography; Extracorpore

1973
[Usefulness of Cardioplegin in surgery with extracorporeal circulation].
    Kardiologia polska, 1973, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Asparagine; Cardiac Surgical Procedures; Child; Child, Pr

1973
Induced ischemic arrest. Clinical experience with cardioplegia in open-heart surgery.
    The Journal of thoracic and cardiovascular surgery, 1972, Volume: 63, Issue:1

    Topics: Adenosine Triphosphate; Adolescent; Adult; Aspartic Acid; Child; Child, Preschool; Female; Heart Arr

1972